"Global Clinical Trials Shift from Europe to US and China"
The focus of global clinical trials is shifting from Europe to the United States and China, according to a recent market analysis. IQVIA, a global healthcare consulting firm, released…
english
english
285 개의 기사가 있습니다.
K-pop Star Nana Confidently Embraces 'No-Bra'...Any Health Benefits?
Nana, a member of the K-pop group After School, recently showcased her no-bra fashion. Nana posted several photos on her Instagram, revealing her current look where she wore a sleeveless…
"SK Biopharm's Epilepsy Drug Excels in the U.S."... Growth Expected in the Second Half
SK Biopharm is expected to continue its performance growth in the second half of the year, driven by the stable sales growth of its epilepsy treatment, Cenobamate (marketed in the…
Singer Kim Jaejoong, Disposes of Frozen Sperm...what happened?
Singer Kim Jaejoong (38) has confessed to disposing of his frozen sperm. Recently, Kim appeared on the YouTube channel ‘Neighborhood Friend Kang Nami’ and discussed his decision to freeze and…
DongA ST, Subsidiary MASH and Obesity Drug Clinical Results Expected This Year
Analysts in the securities industry suggest paying attention to the clinical results to be released later this year by DongA ST's subsidiary, NeuroBo Pharmaceuticals (NeuroBo). On the 12th, Seo Geunhee,…
Biosimilar Onslaught Dents Global Blockbuster Humira
The dominance of the autoimmune disease treatment Humira (active ingredient: adalimumab), once the world's best-selling drug, is waning. Sandoz's biosimilar Hyrimoz has rapidly gained market share, pulling down Humira's share,…
D&D Pharmatech "Confident in MASH and Obesity Drug Efficacy…Targeting 100 Trillion Won Market"
“The GLP-1 obesity treatment market is expected to grow to 100 trillion won( approximately 77 billion dollars) by 2030. Including metabolic-associated steatohepatitis (MASH), the market potential is even larger. D&D…
A New Treatment Option Emerges for Non-Hodgkin's Lymphoma
A new treatment option for managing refractory blood cancer, specifically Diffuse Large B-Cell Lymphoma (DLBCL), has completed its approval process in Korea. This approval primarily targets high-risk patients who frequently…
Hanmi Pharmaceutical Group Declares End to Management Dispute
The management dispute within Hanmi Pharmaceutical Group that has heated up the pharmaceutical and biotech industry for over 6months this year has come to an end. On the 10th, Lim…
Reasons to Watch HK Inno.N in the Second Half of the Year
HK Inno.N Corporation is emerging as a company to watch in the second half of the year, following strong performance and promising U.S. clinical trial results. On the 9th, the…